Skip to main content

Advertisement

SpringerLink
Log in

Investigation of satisfaction with short-term outcomes after switching to faricimab to treat neovascular age-related macular degeneration

  • Clinical Investigation
  • Published:
Japanese Journal of Ophthalmology Aims and scope Submit manuscript

A Correction to this article was published on 10 November 2023

This article has been updated

Abstract

Purpose

To investigate the outcomes and patient satisfaction at 6-months’ follow-up after switching to faricimab to treat neovascular age-related macular degeneration (nAMD) with a treat-and-extend (TAE) regimen.

Study design

Retrospective observational study.

Methods

Forty-eight consecutive eyes (48 patients) were switched to faricimab to treat nAMD and followed for 6 months on a TAE regimen. The Macular Disease Treatment Satisfaction Questionnaire (MacTSQ) was administered to patients 6 months after the switch.

Results

Best-corrected visual acuity (BCVA) was maintained 6 months after the switch, while the mean (± standard error) central foveal thickness 6 months after the switch (272 ± 14 μm) decreased significantly compared to the time of the switch (372 ± 20 μm) (p < 0.001). The interval between injections 6 months after the switch was 10.45 ± 0.44 weeks, a significant extension from 6.72 ± 0.34 weeks at the switch (p = 0.002). The MacTSQ total score (58.8 ± 1.7) in eyes with a BCVA of 20/40 and better 6 months after the switch was significantly higher compared to that in eyes with a BCVA worse than 20/40 (48.2 ± 1.5) (p < 0.001). The MacTSQ total score (56.8 ± 1.8) in eyes in which a 4 weeks extension of the injection interval was achieved was significantly higher than (49.5 ± 1.9) in eyes without (p < 0.001).

Conclusion

Switching to faricimab with a TAE regimen seems to maintain the BCVA and extend the injection interval in patients with nAMD, resulting in enhanced satisfaction.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Change history

References

  1. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419–31.

    Article  CAS  PubMed  Google Scholar 

  2. Heier JS, Brown DM, Chong V, Korobelnik J-F, Kaiser PK, Nguyen QD, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119:2537–48.

    Article  PubMed  Google Scholar 

  3. Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO study. Am J Ophthalmol. 2009;148:43–58.

    Article  CAS  PubMed  Google Scholar 

  4. Rofagha S, Bhisitkul RB, Boyer DS, Sadda SVR, Zhang K, Seven-Up Study Group. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology. 2013;120:2292–9.

    Article  PubMed  Google Scholar 

  5. Wada I, Oshima Y, Shiose S, Kano K, Nakano S, Kaizu Y, et al. Five-year treatment outcomes following intravitreal ranibizumab injections for neovascular age-related macular degeneration in Japanese patients. Graefes Arch Clin Exp Ophthalmol. 2019;257:1411–8.

    Article  CAS  PubMed  Google Scholar 

  6. Maruko I, Ogasawara M, Yamamoto A, Itagaki K, Hasegawa T, Arakawa H, et al. Two-year outcomes of treat-and extend intravitreal aflibercept for exudative age-related macular degeneration. A prospective study. Ophthalmol Retina. 2020;4:767–76.

    Article  PubMed  Google Scholar 

  7. Ohji M, Takahashi K, Okada AA, Kobayashi M, Matsuda Y, Terano Y, et al. Efficacy and safety of intravitreal afliberecept treat-and-extend regimens in exudative age-related macular degeneration: 52- and 96-week findings from ALTAIR: a randomized controlled trial. Adv Ther. 2020;37:1173–87.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Heier JS, Singh RP, Wykoff CC, Csaky KG, Lai TYY, Loewenstein A, et al. The angiopoietin/Tie pathway in retinal vascular diseases. A review. Retina. 2021;41:1–19.

    Article  CAS  PubMed  Google Scholar 

  9. Heier JS, Khanani AM, Ruiz CQ, Basu K, Ferrone PJ, Brittain C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomized, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399:729–40.

    Article  CAS  PubMed  Google Scholar 

  10. Mitchell J, Brose LS, Bradley C. Design of a measure of satisfaction with treatment for macular degeneration (MacTSQ). Qual Life Res. 2007;A-120:2.

    Google Scholar 

  11. Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Culliford LA, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomized controlled trial. Lancet. 2013;382:1258–67.

    Article  CAS  PubMed  Google Scholar 

  12. Morken TS, Knutsen C, Hanseen MS, Austeng D. Patient satisfaction following a switch from treat-and-extend to observe-and-plan regimen in age-related macular degeneration. BMJ Open. 2022;7: e000930. https://doi.org/10.1136/bmjophth-2021-000930.

    Article  Google Scholar 

  13. Boyle J, Vukicevic M, Koklanis K, Itsiopoulos C, Rees G. Experiences of patients undergoing repeated intravitreal anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration. Psychol Health Med. 2018;23:127–40.

    Article  PubMed  Google Scholar 

  14. Droege KM, Muether PS, Hermann MM, Caramoy A, Viebahn U, Kirchof B, et al. Adherence to ranibizumab treatment for neovascular age-related macular degeneration in real life. Graefes Arch Clin Exp Ophthalmol. 2013;251:1281–4.

    Article  CAS  PubMed  Google Scholar 

  15. Holz FG, Schmitz-Valckenberg S, Wolf A, Agostini H, Lorenz K, Pielen A, et al. A randomized, open-label, multicenter study of switching to brolucizumab with or without a loading dose for patients with suboptimal anatomically controlled neovascular age-related macular degeneration-the FALCON study. Graefes Arch Clin Exp Ophthalmol. 2022;260:2695–702.

    CAS  PubMed  PubMed Central  Google Scholar 

  16. Kitajima Y, Maruyama-Inoue M, Ikeda S, Ito A, Inoue T, Yanagi Y, et al. Short-term outcomes of switching to brolucizumab in Japanese patients with neovascular age-related macular degeneration. Jpn J Ophthalmol. 2022;66:511–7.

    Article  CAS  PubMed  Google Scholar 

  17. Yonekawa Y, Andreoli C, Miller JB, Loewenstein JI, Sorbin L, Eliot D, et al. Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration. Am J Ophthalmol. 2013;156:29–25.

    Article  CAS  PubMed  Google Scholar 

  18. Gupta OP, Shienbaum G, Patel AH, Kaiser RS, Regillo CD. A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact. Ophthalmology. 2010;117:2134–40.

    Article  PubMed  Google Scholar 

  19. Rush RB, Rush SW. Intravitreal faricimab for aflibercept-resistant neovascular age-related macular degeneration. Clin Ophthalmol. 2022;16:4041–6.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Leung EH, Oh DJ, Alderson SE, Bracy J, McLeod M, Prez LI, et al. Initial real-world experience with faricimab in treatment-resistant neovascular age-related macular degeneration. Clin Ophthalmol. 2023;17:1287–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Maruko I, Iida T, Saito M, Nagayama D, Saito K. Clinical characteristics of exudative age-related macular degeneration in Japanese patients. Am J Ophthalmol. 2007;144:15–22.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The author thanks Natsuki Kubo, and Haruka Kurabe, CO, for preparation of the data for this study.

Author information

Authors and Affiliations

  1. Hikichi Eye Clinic, Kita-7 Nishi-5 7-1 Kita-Sky-Building, 14 Floor, Kita-ku, Sapporo, 060-0807, Japan

    Taiichi Hikichi

Authors
  1. Taiichi Hikichi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Taiichi Hikichi.

Ethics declarations

Conflicts of interest

T. Hikichi, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events (Chugai).

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Corresponding Author: Taiichi Hikichi

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hikichi, T. Investigation of satisfaction with short-term outcomes after switching to faricimab to treat neovascular age-related macular degeneration. Jpn J Ophthalmol 67, 652–656 (2023). https://doi.org/10.1007/s10384-023-01024-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10384-023-01024-4

Keywords

Search

Navigation